INNO — Innocan Pharma Income Statement
0.000.00%
Last trade - 00:00
- CA$77.27m
- CA$72.08m
- $2.56m
- 53
- 12
- 35
- 25
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0.008 | 0.196 | 2.56 |
Cost of Revenue | |||||
Gross Profit | — | — | 0.003 | 0.121 | 2.11 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 1.17 | 3 | 4.73 | 7.68 | 8.82 |
Operating Profit | -1.17 | -3 | -4.72 | -7.48 | -6.27 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1.19 | -3.33 | -9.95 | -10.1 | -3.89 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.19 | -3.33 | -9.95 | -10.1 | -3.89 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -1.19 | -3.33 | -9.95 | -10 | -3.76 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.19 | -3.33 | -9.95 | -10 | -3.76 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.008 | -0.028 | -0.061 | -0.045 | -0.015 |
Dividends per Share |